The news keeps getting better for the new GLP-1 weight-loss drugs fromEli Lilly and Novo Nordisk.
Positive late-stage trial results come after Novo Nordisk's weekly insulin was rejected by FDA A pair of late-stage trials found that Eli Lilly & Co.'s experimental once-weekly insulin can lower ...
intensifying the company’s race with Novo Nordisk to develop longer-acting insulins. Lilly’s once-weekly insulin, efsitora alfa, reduced the A1C measure of blood sugar comparably to daily ...
Whales with a lot of money to spend have taken a noticeably bearish stance on Novo Nordisk. Looking at options history for Novo Nordisk NVO we detected 9 trades. If we consider the specifics of ...
If you’re on the fence about investing in Eli Lilly And Co or Novo Nordisk A/S (ADR) because you’re not sure how they measure up, it’s important to compare them on a few factors before making your ...
All doses of Novo Nordisk’s Ozempic are expected to face “intermittent shortages” in Europe during the fourth quarter of the year, especially lower doses, ...
Update: Adds company statement about Ozempic availability in the U.S. Novo Nordisk (NVO) has said in a note published by the European Medicines Agency that the supply shortage of its diabetes drug ...
Late last year, Novo Nordisk responded to a growing shortage of popular Ozempic with a plan to cut down on production of its older diabetes med Victoza to make room for more Ozempic. Still ...
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are big pharma peers. They're also each other's biggest rivals, especially in the all-important market for weight-loss drugs, in which both are ...
After a regulatory hiccup earlier this month, Novo Nordisk’s heart failure ambitions for its obesity star Wegovy (semaglutide) are starting to get back on track. Novo’s semaglutide cut the ...
LONDON — After a recent spate of setbacks, Novo Nordisk has raised the curtain on data detailing semaglutide’s ability to cut the risk of heart failure … ...
Novo Nordisk’s obesity drug Wegovy cut the risk of severe complications in patients with a common form of heart failure, according to a new analysis that could boost the company’s efforts to ...